Your browser is no longer supported. Please, upgrade your browser.
Dr. Reddy's Laboratories Limited
Index- P/E46.44 EPS (ttm)1.53 Insider Own27.70% Shs Outstand166.70M Perf Week-0.96%
Market Cap11.85B Forward P/E34.25 EPS next Y2.08 Insider Trans0.00% Shs Float121.87M Perf Month3.80%
Income254.20M PEG3.66 EPS next Q0.52 Inst Own13.70% Short Float0.64% Perf Quarter4.01%
Sales2.46B P/S4.82 EPS this Y3.80% Inst Trans-0.21% Short Ratio4.96 Perf Half Y29.27%
Book/sh11.58 P/B6.14 EPS next Y17.56% ROA- Target Price69.82 Perf Year72.22%
Cash/sh- P/C- EPS next 5Y12.70% ROE- 52W Range33.33 - 73.50 Perf YTD-0.32%
Dividend0.33 P/FCF- EPS past 5Y-2.00% ROI9.90% 52W High-3.32% Beta0.40
Dividend %0.46% Quick Ratio- Sales past 5Y3.30% Gross Margin54.80% 52W Low113.20% ATR1.18
Employees21650 Current Ratio- Sales Q/Q2.00% Oper. Margin9.50% RSI (14)54.96 Volatility1.26% 1.42%
OptionableYes Debt/Eq- EPS Q/Q-30.40% Profit Margin8.50% Rel Volume1.04 Prev Close72.01
ShortableYes LT Debt/Eq- EarningsJan 29 BMO Payout- Avg Volume157.75K Price71.06
Recom2.00 SMA200.38% SMA504.96% SMA20018.68% Volume164,027 Change-1.32%
Sep-18-20Upgrade Investec Sell → Hold
Sep-18-20Upgrade BofA Securities Neutral → Buy
Jan-28-20Downgrade CLSA Buy → Outperform
Jan-27-20Downgrade CLSA Buy → Outperform
Jan-09-20Upgrade Citigroup Sell → Buy
Nov-04-19Downgrade BofA/Merrill Buy → Neutral
Sep-04-19Upgrade Credit Suisse Underperform → Outperform
Jul-01-19Upgrade Macquarie Neutral → Outperform
Jun-20-19Initiated Deutsche Bank Hold
Jun-11-19Initiated Barclays Equal Weight $39
May-20-19Downgrade Morgan Stanley Overweight → Equal-Weight
Feb-19-19Upgrade CLSA Outperform → Buy
Jan-17-19Downgrade Citigroup Neutral → Sell
Sep-21-17Upgrade Morgan Stanley Equal-Weight → Overweight
Aug-31-17Upgrade CLSA Underperform → Outperform
Jul-28-17Downgrade CLSA Underperform → Sell
Jul-27-16Downgrade Jefferies Hold → Underperform
Jul-27-16Downgrade HSBC Securities Hold → Reduce
Feb-10-16Upgrade Credit Agricole Underperform → Buy
Nov-10-15Downgrade Citigroup Buy → Neutral
Jan-15-21 12:33PM  
Jan-11-21 10:25AM  
Jan-08-21 08:21AM  
Dec-22-20 01:11AM  
Dec-14-20 12:51PM  
Dec-09-20 04:20AM  
Dec-01-20 08:15AM  
Nov-28-20 11:33AM  
Nov-12-20 10:47AM  
Nov-09-20 09:14AM  
Oct-29-20 11:24AM  
Oct-28-20 06:09AM  
Oct-20-20 03:44AM  
Oct-17-20 06:44AM  
Oct-12-20 08:51AM  
Oct-05-20 05:27AM  
Oct-03-20 02:57AM  
Oct-01-20 04:08AM  
Sep-26-20 06:03AM  
Sep-25-20 03:16AM  
Sep-22-20 05:23AM  
Sep-17-20 03:50PM  
Sep-16-20 04:25PM  
Sep-14-20 12:32PM  
Sep-09-20 09:13AM  
Sep-07-20 08:34AM  
Sep-03-20 03:04AM  
Aug-27-20 03:52AM  
Aug-19-20 04:17AM  
Aug-13-20 05:33PM  
Aug-11-20 12:30AM  
Jul-29-20 06:47AM  
Jul-27-20 08:31AM  
Jul-20-20 07:59AM  
Jul-14-20 04:45AM  
Jul-08-20 08:59AM  
Jul-06-20 07:07AM  
Jul-05-20 05:05PM  
Jul-01-20 04:10AM  
Jun-19-20 05:39AM  
Jun-16-20 01:48AM  
Jun-15-20 10:32AM  
Jun-13-20 05:15AM  
Jun-12-20 07:44AM  
Jun-11-20 02:45PM  
Jun-10-20 05:49AM  
May-21-20 09:56AM  
May-20-20 03:15PM  
May-07-20 04:50AM  
May-06-20 01:15PM  
Apr-27-20 03:07AM  
Apr-24-20 11:42AM  
Apr-17-20 08:55AM  
Apr-14-20 05:22AM  
Apr-13-20 06:17PM  
Apr-08-20 10:28AM  
Mar-27-20 06:45PM  
Mar-26-20 02:03PM  
Mar-22-20 08:29PM  
Mar-21-20 09:29AM  
Mar-20-20 01:38AM  
Mar-19-20 02:50AM  
Mar-17-20 05:53AM  
Mar-06-20 06:50AM  
Feb-27-20 04:03AM  
Feb-14-20 11:41AM  
Feb-07-20 03:02AM  
Feb-06-20 08:30AM  
Jan-30-20 07:00AM  
Jan-28-20 10:20AM  
Jan-27-20 04:32AM  
Jan-10-20 10:14AM  
Dec-30-19 04:57AM  
Dec-20-19 04:41AM  
Dec-13-19 12:00PM  
Dec-06-19 03:29AM  
Dec-04-19 02:49AM  
Nov-22-19 04:48AM  
Nov-15-19 08:42AM  
Nov-13-19 09:22AM  
Nov-11-19 08:42AM  
Dr. Reddy's Laboratories Limited operates as an integrated pharmaceutical company worldwide. It operates through three segments: Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Proprietary Products. Dr. Reddy's Laboratories Limited operates as an integrated pharmaceutical company worldwide. It operates through three segments: Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Proprietary Products. The Global Generics segment manufactures and markets prescription and over-the-counter finished pharmaceutical products that are marketed under a brand name or as a generic finished dosage with therapeutic equivalence to branded formulations. This segment also engages in the biologics business. The PSAI segment manufactures and markets active pharmaceutical ingredients and intermediates, which are principal ingredients for finished pharmaceutical products. It also provides contract research services; and manufactures and sells active pharmaceutical ingredients and steroids in accordance with the specific customer requirements. The Proprietary Products segment focuses on the research, development, and manufacture of differentiated formulations for dermatology and neurology therapeutic areas. The company also engages in developing therapies in the fields of oncology and inflammation. As of March 31, 2020, it had four late stage projects at various stages of development. The company's therapeutic categories primarily include gastro-intestinal, cardiovascular, anti-diabetic, dermatology, oncology, respiratory, stomatology, urology, and nephrology. It has collaboration, license, and option agreement with Curis, Inc. to discover, develop, and commercialize small molecule antagonists; and partnership with Department of Biotechnology - Biotechnology Industry Research Assistance Council for Sputnik V vaccine clinical trials in India. The company was founded in 1984 and is headquartered in Hyderabad, India.